文献速递泌尿生殖与妇科肿瘤放疗

铱植入联合外照射与单纯外照射治疗淋巴结阴性局部晚期前列腺癌的随机试验长期结果

Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-05-17

该随机试验纳入104例cT2-3、手术分期淋巴结阴性前列腺癌患者,比较铱植入联合外照射(40 Gy/20次+35 Gy/48小时)与单纯外照射(66 Gy/33次)的长期生存影响。中位随访14年,两组总生存、前列腺癌特异性死亡及转移均无显著差异,但联合治疗组的生化控制改善得以维持。

要点

  • 联合铱植入未改善总生存(HR 1.00,95%CI 0.63-1.59)。
  • 前列腺癌特异性死亡无差异(HR 0.79,95%CI 0.34-1.87)。
  • 生化控制改善维持(HR 0.53,95%CI 0.31-0.88)。

核心结论

  • 尽管生化复发率大幅降低,但铱植入联合外照射未转化为总生存或前列腺癌特异性生存的改善。

研究设计与样本

  • 1992年至1997年随机对照试验,纳入104例cT2-3、手术分期淋巴结阴性前列腺癌患者,随机接受铱植入联合外照射或单纯外照射。
  • 联合组接受外照射40 Gy/20次联合铱植入35 Gy/48小时;单纯组接受外照射66 Gy/33次。
  • 根据T分期、Gleason评分和前列腺特异性抗原水平,60%患者为高危疾病。
  • 中位随访14年,5例失访,其余患者至少随访13年。

主要发现

  • 共75例死亡,其中前列腺癌死亡21例,第二癌症死亡25例;发生第二癌症的患者无前列腺癌死亡。
  • 联合组死亡34例(67%),单纯组死亡41例(77%),总生存无差异(HR 1.00,95%CI 0.63-1.59)。
  • 前列腺癌特异性死亡:联合组9例(18%),单纯组12例(23%),无差异(HR 0.79,95%CI 0.34-1.87)。
  • 转移性疾病:联合组10例(20%),单纯组15例(28%),无统计学显著差异(HR 0.70,95%CI 0.32-1.57)。
  • 生化控制改善得以维持(HR 0.53,95%CI 0.31-0.88)。

关键数值与推荐

  • 联合组外照射40 Gy/20次联合铱植入35 Gy/48小时;单纯组外照射66 Gy/33次。
  • 总生存HR 1.00(95%CI 0.63-1.59);前列腺癌特异性死亡HR 0.79(95%CI 0.34-1.87);转移HR 0.70(95%CI 0.32-1.57);生化控制HR 0.53(95%CI 0.31-0.88)。

临床怎么用

  • 对于淋巴结阴性局部晚期前列腺癌,铱植入联合外照射虽改善生化控制,但未显示总生存或前列腺癌特异性生存获益。

局限性

  • 样本量较小(104例),可能影响统计效能。
  • 5例失访,但其余患者随访至少13年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the impact on long-term survival from the addition of brachytherapy to external beam radiation therapy (EBRT) in patients with prostate cancer. METHODS AND MATERIALS: Between 1992 and 1997, 104 men with cT2-3, surgically staged node-negative prostate cancer were randomized to receive either EBRT (40 Gy/20 fractions) with iridium implant (35 Gy/48 hours) or EBRT alone (66 Gy/33 fractions) to the prostate. According to T stage, Gleason score, and prostate-specific antigen level, 60% of patients had high-risk disease. Substantial improvements in biochemical control at 8 years have previously been reported. Additional follow-up was collected on deaths and metastases. RESULTS: Median follow-up was 14 years. Five patients were lost to follow-up. All other patients have been followed a minimum of 13 years. There have been 75 deaths, including 21 from prostate cancer and 25 from second cancers. No patients developing a second cancer have died from prostate cancer. There was no difference in overall survival between the 2 treatment groups: 34 deaths (67%) in the implant arm and 41 (77%) in the EBRT arm (hazard ratio [HR] 1.00, 95% confidence interval [CI] 0.63-1.59). Similarly, there was no difference in prostate cancer-specific deaths: 9 (18%) patients in the implant arm compared with 12 (23%) in the EBRT arm (HR 0.79, 95% CI 0.34-1.87). There was no statistically significant difference in the number of patients developing metastatic disease: 10 (20%) in the implant arm and 15 (28%) in the EBRT arm (HR 0.70, 95% CI 0.32-1.57). Improvements in biochemical control were maintained (HR 0.53, 95% CI 0.31-0.88). CONCLUSIONS: Despite a dramatic reduction of biochemical recurrence rates, the addition of iridium implant to EBRT did not translate into improved overall survival or prostate cancer-specific survival.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Dayes IS, Parpia S, Gilbert J, et al. Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. Int J Radiat Oncol Biol Phys. 2017. PMID: 28816169. doi:10.1016/j.ijrobp.2017.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。